The Biden administration moved a step closer yesterday to rescinding a Trump administration rule governing what 340B health centers can charge patients for insulin and epinephrine auto-injectors. | Shutterstock

White House Clears Path for HRSA to Rescind Trump’s Health Center 340B Insulin Rule

The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The final rule currently is due to take effect on July 20.

OMB finished reviewing the U.S. Health Resources and Services Administration’s (HRSA’s) recission proposal yesterday. HRSA could post its proposal, in the form of a proposed rule, for public inspection on the Federal Register website as soon as later today. There probably will be a public comment period, followed by another OMB review, before publication of a final rule later this summer rescinding the Trump-era mandate.

The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The final rule currently is due to take effect on July 20.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts